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Background: The over-all age-adjusted prevalence of diabetes mellitus type 2 (DMT2) in Saudi Arabia is unprecedented
at 31%. Aggressive measures should be done to curb down increasing incidence. In this prospective 6-month study we
aim to determine whether a self-monitoring, life-style modification program that includes increased sunlight exposure
confer improvement in vitamin D status and health benefits among adult Saudi overweight and obese patients with
varying glycemic status.
Methods: A total of 150 overweight and obese Saudi adults with varying glycemic status aged 30–60 years were
included in this study. They were divided into 3 groups (Non-DMT2, Pre-diabetes and DMT2). Baseline anthropometrics
and blood glucose were taken at baseline and after 6 months. Fasting blood sugar, lipid profile, calcium, albumin and
phosphate were measured routinely. Serum 25(OH) vitamin D was measured using standard assays. Within the time
period they were instructed to reduce total intake of fat, increased fiber intake and increase sun exposure.
Results: In all groups there was a significant improvement in vitamin D levels as well as serum triglycerides, LDL- and
total cholesterol. However, a significant increase in serum glucose levels was noted in the non-DMT2 group, and a
significant decrease in HDL-cholesterol in both non-DMT2 and pre-diabetes group. In the pre-diabetes group, 53.2%
were able to normalize their fasting blood levels after 6 months, with 8.5% reaching the DMT2 stage and 38.3%
remaining pre-diabetic. In all groups there was a significant increase in the prevalence of hypertension.
Conclusion: Improving vitamin D status with modest lifestyle modifications over a short-period translates to
improvement in lipid profile except HDL-cholesterol among overweight and obese Saudi adults, but not BMI and
blood pressure. Findings of the present study merit further investigation as to whether full vitamin D status correction
can delay or prevent onset of DMT2.
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If the prevalence of diabetes mellitus type 2 (DMT2)
continues to increase at the current rate, the global bur-
den of this disease will swell between from 171 million
in 2000, to 366 million patients in 2030 [1]. Further-
more, healthcare expenditures on DMT2 alone will
skyrocket from US$376 billion in 2010 to US$490 bil-
lion in 2030 [2]. The Middle East region has not been
spared from this scourge and currently is among those
worst-hit [1]. This global epidemic, shared by both in-
dustrialized and developing countries, has stimulated
increased public awareness of the disease, the identifi-
cation of risk factors and the knowledge that DMT2
can be delayed and, even better, prevented [3-5]. Rec-
ognition of the importance of glycemic control in the
prevention of the complications and morbidity of DMT2
has led to worldwide campaigns for modifications in
lifestyle and an intensive search for better anti-diabetes
medications [6-8].
Harboring pre-diabetes, or state of intermediate hyper-
glycemia (plasma glucose levels higher than normal, but
lower than the threshold of DM), puts an individual at
high risk not only for developing DM but associated
complications as well. Among the Gulf neighboring coun-
tries, the prevalence of pre-diabetes based on several
low-moderate sample-sized cross-sectional studies is
moderately high: 9.0% in Saudi Arabia [9], 13.8% in Qatar
[10], 40.9% in Oman [11], and 24.2% in United Arab
Emirates (UAE) [12]. According to an expert from the
American Diabetes Association (ADA), almost 70% of
the pre-diabetes population will eventually develop DMT2,
and in over a 3- to 5-year period, persons who harbor
pre-diabetes have a 5- to 15-fold higher risk of further
progressing to DMT2 as opposed to their normogly-
cemic counterparts [13,14]. Having mentioned such and
considering the global economic burden of DMT2, not to
mention the perpetual obstacles to deliver high-quality
standard care to DMT2 patients, the challenge to fight
DMT2 through prevention is a compelling case worthy of
attention and enormous investigation.
Fortunately during the recent years, there has been ac-
cumulating evidence from various interventional studies
on the beneficial effects of improving vitamin D status
among patients with DMT2 and the full metabolic syn-
drome [15-17]. This suggests some important clinical
implications among patients at risk of developing DMT2.
However, there is limited information on the role of im-
proving vitamin D status among patients with pre-
diabetes, specifically in this region where the prevalence of
both DMT2 and vitamin D deficiency are high. Having
mentioned such, the present interventional study aims to
determine whether a self-monitoring, life-style modi-
fication program that includes increased sunlight ex-
posure confer improvement in vitamin D status and healthbenefits among adult Saudi overweight and obese patients
with varying glycemic status.
Methods
Site and duration of the study
This is a multi-center, interventional study to be conducted
at the primary care centers of the RIYADH Cohort, a
capital-based screening program involving more than
17000 Saudi subjects randomly selected to participate in
epidemiologic studies conducted by the Biomarkers Re-
search Program (BRP) of King Saud University (KSU) and
the Ministry of Health (MOH), Riyadh, Saudi Arabia.
Subjects
A total of 200 Saudi adult males and females aged 30–60
years old with unknown DM status and varying body
mass indices (BMI) were initially recruited to take part
in this 6-month interventional study. These subjects were
recruited from the community participants of the Saudi
Diabetes Charity Foundation based in Riyadh, Saudi
Arabia. Out of the 200 subjects, 50 dropped out for vari-
ous reasons (non-compliance, change of medication, lost
to follow up, etc.). They were divided into 3 groups based
on baseline fasting blood glucose (FBG) levels: Non-
DMT2 group (FBG < 5.6 mmol/l), Pre-DMT2 group (FBG
5.6-6.9 mmol/l) and DMT2 group (FBG ≥ 7.0 mmol/l).
Non-consenting subjects, pregnant subjects, and anyone
with complications such as renal, neurologic, hepatic and
pulmonary diseases were excluded as well as acute condi-
tions that require immediate medical attention. The study
was performed in accordance with the the ethical princi-
ples in the Declaration of Helsinki as well as with the ICH
Note for Guidance on Good Clinical Practice. Approval
from the ethics committee of the College of Science, KSU
was sought prior to study commencement.
Clinical assessment
Baseline anthropometric measurements were noted by
the assigned and registered primary care physician and
nurse. These included height (cm) and weight (kg) from
which BMI was calculated [weight (kg)/height (m2)].
Blood pressure (mmHg) was taken twice after 30 minutes
rest using the conventional mercurial sphygmomanom-
eter and the average was recorded. All measurements
were repeated after 6 months.
Laboratory parameters
All subjects were requested to submit an over-night fast-
ing blood samples from which the different metabolic
parameters were assessed. Serum FBG, complete lipid
profile, serum albumin, calcium and phosphate were deter-
mined using routine laboratory methods. Serum 25(OH)
vitamin D was measured using an enzyme-linked immuno-
sorbent assay (ELISA) (IDS Ltd., Boldon Colliery, Tyne &
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5.3% and 4.6%. All measurements were done in a DEQAS-
(Vitamin D External Quality Assessment Scheme) partici-
pating laboratory, the Biomarkers Research Program (BRP)
of King Saud University, Riyadh, KSA.
Lifestyle intervention
All subjects were oriented and educated about lifestyle
modifications from successful intervention programs
done elsewhere [18,19], advised and followed-up regu-
larly during specified visits. In brief, the intervention
program has specific goals which include weight reduc-
tion of 5% or more, total intake of fat to < 30% of energy
consumed, intake of saturated fat < 10% of energy con-
sumed, increased fiber intake to at least 15 g/1000 kcal
and moderate exercise for at least 30 minutes per day
(30 minute walk, 5 times a week). Some of these goals
are exemplified as taken from the Diabetes Prevention
Program (DPP): eat smaller portions; drink more water
and little or no sugar-containing beverages each day;
choose leaner cuts of beef, eat white meat of turkey and
chicken more often, eat fish high in omega-3; fatty acids,
and no more than 340 gram per week; increase intake
of whole fruits and vegetables; choose whole grains
like rolled oats, barley, bran, and 100% whole grain
bread instead of refined, processed carbohydrates like
baked products made with white flour; choose low or
no fat dairy products; use unsaturated vegetable oils
that are liquid at room temperature like olive, canola,
peanut, safflower, sunflower, corn, soybean and cot-
tonseed oils, and use soft-tub, squeeze or spray margarine;
eat at regular mealtimes; use low-fat food preparation
(grilling, broiling, boiling, steaming, etc.…); eat breakfast
and reduce frequency of eating out, especially in fast food
restaurants [20].
The orientation and intervention were conducted by a
certified nutritionist, physician, nurse and physical thera-
pists, who were also the same team that reinforced in-
structions to the subjects on a regular basis. In addition,
they were advised to increase sunlight exposure dur-
ing the entire 6 months of the study. In all subjects,
“self-monitoring” was introduced, and they were sub-
jected to regular calls from the investigator to keep track
of the progress.
Data analysis
Collected data was analyzed using SPSS version 16.5 for
windows (Chicago, Illinois, USA). Frequencies were pre-
sented in percent (%) cases and Chi-square was used to
determine differences. Paired T-test was done to deter-
mine intervention effects in anthropometric and meta-
bolic parameters at baseline and after 6 months. Bivariate
correlation coefficients between the variables were deter-
mined. P-value ≤ 0.05 will be considered significant.Results
Table 1 highlights the characteristics of all subjects and
the non-diabetic group. In all subjects, no significant
changes were observed in BMI, blood pressure and fast-
ing blood glucose overtime. Serum triglycerides, total
cholesterol, LDL- and HDL-cholesterol significantly de-
creased after 6 months compared to baseline (p-values
0.048, 5.3 x 10−6, 2.5 x 10−5 and 3.0 x 10−4, respectively).
On the other hand, baseline serum calcium and albumin
were noted to be significantly higher as compared to
6 months (p-values 1.1 x 10−7 and 0.026, respectively.
There was also a significant increase in levels of circulating
25(OH) vitamin D from baseline to 6 months (p-value
3.3 x 10−4). In the non-diabetic group, baseline BMI and
blood pressure remained almost unchanged after 6 months
follow-up. However, a significant increase in fasting serum
glucose was noted after 6 months (p-value 0.0002). With
regards to lipids, changes in baseline serum triglycer-
ides, total and LDL-cholesterol were not significant after
6 months follow-up. However, follow-up HDL-cholesterol
was significantly higher as compared to baseline levels
(p-value 0.0002). Baseline serum albumin levels signifi-
cantly increased after 6 months as well as baseline serum
25(OH) vitamin D (p-values 0.004, 0.004 respectively).
Table 2 shows the metabolic changes in both the
DMT2 group and the pre-diabetes group. In both
groups, no significant improvements were observed in
BMI, blood pressure, serum glucose and triglycerides
over time. However, and also in both groups, a signifi-
cant decrease was observed in serum total and LDL-
cholesterol (DMT2 group p-values 0.0004 and 7.6 x 10−5;
pre-DM group p-values 0.002 and 0.017, respectively.
Changes in HDL-cholesterol were noted only in the pre-
DM group, in which baseline levels were significantly
higher than after 6 months (p-value 0.009). Serum calcium
levels on the other hand significantly increased from base-
line to 6 months in both groups (DMT2 group p-value
0.015; pre-DM group = 0.012). Lastly, improvements in 25
(OH) vitamin D levels were noted only in the pre-DM
group, with borderline significance (p-value 0.05).
Table 3 shows the associations of serum 25(OH) vita-
min D to baseline anthropometric and metabolic param-
eters as well as after 6 months. In all subjects, only
serum calcium was positively associated with 25(OH)
vitamin D levels (R = 0.19; p-value < 0.05). This was also
true for the pre-DM group (R = 0.27; p-value 0.05) while
for the non-DMT2 group, serum calcium was significantly
associated with 25(OH) vitamin D only at baseline)
R = 0.27; p-value < 0.05). With regards to lipids, serum tri-
glycerides and total cholesterol were both negatively and
significantly associated with 25(OH) vitamin D levels, but
only in the pre-DM group at baseline (R = −0.27 and −0.29,
respectively). In the DMT2 group, only serum phosphate
was significantly associated with 25(OH) vitamin D levels
Table 1 Anthropometric and metabolic changes of all subjects and non-DM group over time
All subjects Non-DMT2 group
Baseline 6 months P-value Baseline 6 months P-value
M/F 37/113 15/51
Age (years) 44.78 ± 0.93 39.8 ± 1.44
BMI (kg/m2) 32.3 ± 0.5 32.2 ± 0.5 NS 32.6 ± 0.8 32.5 ± 0.8 NS
Systolic blood pressure (mmHg) 115.7 ± 1.7 115.4 ± 1.8 NS 115.4 ± 2.4 114.6 ± 2.5 NS
Diastolic blood pressure (mmHg) 84.8 ± 2.2 85.1 ± 24.7 NS 81.2 ± 3.3 82.6 ± 3.3 NS
Glucose (mmol/l) 6.1 ± 0.2 6.0 ± 0.2 NS 4.6 ± 0.1 5.2 ± 0.1 0.0002
Triglycerides (mmol/l) 1.7 ± 0.07 1.6 ± 0.06 0.048 1.62 ± 0.1 1.47 ± 0.08 NS
Total cholesterol (mmol/l) 4.7 ± 0.09 4.3 ± 0.08 5.3 × 10−6 4.6 ± 0.13 4.3 ± 0.11 NS
HDL-cholesterol (mmol/l) 1.1 ± 0.03 0.87 ± 0.05 3.0 × 10−4 1.1 ± 0.04 0.84 ± 0.07 0.002
LDL-cholesterol (mmol/l) 3.5 ± 0.11 3.1 ± 0.09 2.5 × 10−5 3.3 ± 0.14 3.06 ± 0.12 NS
Calcium (mmol/l) 2.1 ± 0.01 2.2 ± 0.01 1.1 × 10−7 2.07 ± 0.02 2.23 ± 0.02 0.0008
Corrected calcium (mmol/l) 2.2 ± 0.01 2.3 ± 0.01 7.3 × 10−8 2.17 ± 0.02 2.28 ± 0.02 0.001
Phosphate (mmol/l) 1.08 ± 0.05 1.11 ± 0.02 NS 1.08 ± 0.12 1.09 ± 0.02 NS
Albumin (g/l) 36.4 ± 0.46 37.6 ± 0.37 0.026 35.2 ± 0.68 37.6 ± 0.6 0.004
25-OH D (nmol/l) 45.7 ± 2.2 55.8 ± 2.7 3.3 x 10−4 42.3 ± 2.8 53.6 ± 3.6 0.004
Note: Data presented as mean ± standard error; NS – not significant; significance at p < 0.05.
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rest of the associations were non-contributory.
Lastly, Table 4 shows the changes in the cardiometa-
bolic risk factors from baseline and after 6 months. In
Figure 1, the most notable changes were observed in the
glycemic status, in which all those who were non-DMT2
at baseline dropped to 70% after follow-up, with 25.4%




Age (years) 47.69 ± 1.45
BMI (kg/m2) 31.8 ± 1.0 32.1 ± 0.9
Systolic blood pressure (mmHg) 115.7 ± 3.6 116.2 ± 4.4
Diastolic blood pressure (mmHg) 90.8 ± 4.9 89.7 ± 5.6
Glucose (mmol/l) 8.6 ± 0.4 7.8 ± 0.4
Triglycerides (mmol/l) 2.0 ± 0.17 1.9 ± 0.12
Total cholesterol (mmol/l) 5.0 ± 0.21 4.3 ± 0.17
HDL-cholesterol (mmol/l) 0.98 ± 0.06 0.94 ± 0.11
LDL-cholesterol (mmol/l) 3.8 ± 0.3 2.97 ± 0.2
Calcium (mmol/l) 2.1 ± 0.03 2.2 ± 0.04
Corrected calcium (mmol/l) 2.2 ± 0.02 2.3 ± 0.03
Phosphate (mmol/l) 1.08 ± 0.03 1.1 ± 0.04
Albumin (g/l) 37.4 ± 0.9 38.1 ± 0.7
25-OH D (nmol/l) 46.8 ± 3.6 54.7 ± 4.8
Note: Data presented as mean ± standard error; NS – not significant; significance atDMT2. In the baseline pre-DM group, 53.2% were able
to normalize their fasting blood levels after 6 months,
with 8.5% reaching the DMT2 stage and 38.3% remaining
pre-diabetic. Finally in the baseline DMT2 group, 13.2%
were able to normalize their fasting blood glucose after
6 months, with 36.8% also improving but still in the pre-
diabetes stage and 50% remaining well within the cut-off of
DMT2. In all groups there was a significant increase in there-diabetes group over time
Pre-diabetes group
P-value Baseline 6 months P-value
14/33
48.85 ± 1.46
NS 32.2 ± 0.97 32.0 ± 0.92 NS
NS 116.3 ± 3.5 115.8 ± 3.2 NS
NS 85.3 ± 3.5 85.0 ± 3.8 NS
NS 6.1 ± 0.05 5.8 ± 0.17 NS
NS 1.7 ± 0.12 1.6 ± 0.11 NS
0.0004 4.8 ± 0.14 4.3 ± 0.13 0.002
NS 1.07 ± 0.05 0.86 ± 0.08 0.009
7.6 x 10−5 3.6 ± 0.18 3.1 ± 0.16 0.017
0.015 2.09 ± 0.02 2.18 ± 0.02 0.012
0.002 2.15 ± 0.02 2.23 ± 0.02 0.005
NS 1.08 ± 0.02 1.08 ± 0.02 NS
NS 37.4 ± 0.87 37.3 ± 0.52 NS
NS 49.3 ± 5.2 60.7 ± 5.8 0.05
p < 0.05.
Table 3 Associations of 25(OH) vitamin D to metabolic parameters according to groups
ALL subjects N = 150 Non-DMT2 group N = 67 Pre-DM group N = 47 DMT2 group N = 37
Baseline 6 months Baseline 6 months Baseline 6 months Baseline 6 months
BMI (kg/m2) −0.10 −0.11 0.06 0.07 −0.19 −0.34* −0.06 −0.03
Systolic blood pressure (mmHg) 0.10 −0.04 0.05 0.00 0.01 −0.02 0.21 −0.20
Diastolic blood pressure (mmHg) 0.03 −0.05 0.08 −0.10 −0.06 −0.18 −0.04 0.16
Glucose (mmol/l) 0.07 0.15 0.05 0.04 0.008 0.23 0.02 0.20
Triglycerides (mmol/l) −0.04 −0.04 0.04 0.04 −0.11 −0.27* −0.14 0.18
Total cholesterol (mmol/l) −0.10 −0.15 −0.02 −0.10 −0.20 −0.29* −0.11 −0.03
HDL-cholesterol (mmol/l) −0.06 −0.05 0.05 −0.13 −0.28 −0.02 0.09 0.12
LDL-cholesterol (mmol/l) −0.05 −0.14 0.02 −0.06 −0.05 −0.22 −0.15 −0.14
Calcium (mmol/l) 0.05 0.19* 0.27* 0.23 −0.04 0.27* −0.32 0.10
Corrected calcium (mmol/l) −0.02 0.15 0.20 0.17 −0.23 0.22 −0.11 0.09
Phosphate (mmol/l) −0.02 0.07 0.19 0.16 −0.23 −0.19 0.00 0.34*
Albumin (g/l) 0.07 0.09 0.12 0.12 0.13 0.06 −0.19 0.08
Note: Data presented as coefficient (R); *denotes significance at p < 0.05.
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the prevalence of hypertriglyceridemia was observed in the
pre-DM group. Regardless of the glycemic status at base-
line, there was a significant improvement in vitamin D
status, with baseline vitamin D deficiency dropping signifi-
cantly in all groups, but still high over-all (Table 4).
Discussion
The significant finding of the present interventional
study was that the over-all improvement in the vitamin
D status of the cohort after 6 months, as evidenced by
the significant decrease in mean vitamin D levels and
vitamin D deficiency prevalence, led to modest improve-
ments at most, in the lipid profile that includes triglycer-
ides, LDL- and total cholesterol, with no improvements
observed in BMI and blood pressure. Furthermore, vita-
min D status was not associated with majority of the
metabolic parameters measured, with only triglycerides
showing a positive association among patients with pre-
diabetes and serum calcium in all subjects which was ex-
pected, considering that vitamin D is the main regulator
of calcium homeostasis. This lack of promising clinical
benefits highlights several caveats in the intervention
program, particularly the “self-monitoring” strategy thatTable 4 Changes in risk factors over time
Non-DMT2 group N = 67
Baseline 6 months P-value Baselin
Obesity 64.7 64.7 NS 64.3
Hypertension 23.6 26.0 0.006 21.4
Hypertriglyceridemia 32.4 32.4 NS 46.8
Vitamin D deficiency 67.6 52.2 0.009 55.3
Note: Data presented as percentages (%); NS – not significant; significance at p < 0.the investigators employed. Nevertheless, interventional
studies done elsewhere among patients with pre-diabetes
also observed that raising vitamin D levels either through
supplementation for 3 months one year had no effect on
insulin sensitivity, pathophysiology of pre-diabetes and de-
velopment of diabetes [21,22].
Another possible explanation for the lack of profound
clinical improvement was that despite the significant im-
provement of vitamin D status across all groups, the
BMI status remained constant, which is the main target
of successful programs designed to reduce diabetes risk.
The biggest and most convincing documentation for the
risk-reducing benefits of lifestyle modification in the
USA were studies from the Diabetes Prevention Program
(DPP), which apparently was also the first randomized
trial to compare lifestyle and a pharmacologic interven-
tion to placebo [20]. Based on the DPP plan, weight re-
duction was the most powerful predictor of reduced
diabetes incidence with an over-all 16.0% risk reduction
for every 1 kg of reduced weight [23]. Nevertheless,
people who achieved physical exercise instead of weight
loss also experienced significant reduction in diabetes
risk by as much as 44%. Modifications in physical activ-
ity and reduction of calories from dietary fat predictedPre-DM group N = 47 DMT2 group N = 37
e 6 months P-value Baseline 6 months P-value
61.9 NS 64.7 67.6 NS
34.3 0.0001 33.3 51.6 0.008
38.3 0.04 48.6 52.6 NS
52.2 0.008 62.2 48.6 0.04
05.
Figure 1 Prevalence of fasting glycemic states at baseline and after 6 months in non-DMT2, Pre-DM and DMT2 groups.
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betes risk, further confirming the premise that interces-
sions to decrease diabetes risk should target weight
reduction especially in the overweight and obese popula-
tion. It is worthy to note however that despite the lack
of significant BMI loss, the glycemic status of the DMT2
group improved, with 50% of the subjects having lower
fasting blood glucose levels as compared to their base-
line levels. This however is overshadowed by the control
group, who, in sharp contrast, had significantly higher
mean levels of serum glucose after the intervention.
Another finding worthy of mention is the significant
decrease in HDL-cholesterol in all groups despite im-
provements in the rest of the lipid profile. This finding
is in line with several recently published studies ques-
tioning whether vitamin D status correction, at least
among those who are vitamin D deficient, have no
meaningful clinical changes in lipid concentrations, if
not negative effect among those who were not vitamin D
deficient [24,25]. This may have been the case in the
present cohort, where vitamin D sufficiency is present
within 30-40% across groups. Low HDL-cholesterol is
already the most common metabolic syndrome compo-
nent among Saudis with 90% of adults harboring such
condition [26], and if previous claims are true on the
negative effects on lipids on those patients who are
not vitamin D deficient, then further investigations are
needed to target only those who are most at risk for
vitamin D deficiency, and exclude those whose vitamin D
status are normal. Emerging indices for insulin resistance
such as visceral adiposity index (VAI) are also suggested
to be included in future studies to probe specific im-
provements outside conventional parameters used in the
present study [27].
The present study has several caveats and findings
should be interpreted with caution. It may have been
underpowered with a short duration of intervention.
The method of “self-monitoring” have made the resultsless beneficial but still favorable, since compliance and
adherence is highly linked to the success of the program.
Season should have been taken into consideration since
it affects vitamin D status in the region [28]. Neverthe-
less the study has merits in being the first interventional
study to observe the effects of sub-optimal vitamin D
status replenishment in overweight and obese adults
with varying degrees of glycemia in the Middle East.
Conclusion
In summary, self-monitoring lifestyle modification coupled
with increased sun exposure for 6 months improved, but
not corrected vitamin D status, with no immediate impact
in BMI, blood pressure and glucose levels among Saudi
overweight and obese patients with pre-diabetes and
DMT2. Significant improvements were most notable in
lipid profile, with the exception of HDL-cholesterol, which
decreased in all groups. Further interventional studies with
a cohort exclusively to those with vitamin D deficiency and
a more aggressive approach such as full vitamin D correc-
tion through supplementation in the implementation of
lifestyle modifications is warranted to elicit a more favor-
able clinical improvement.
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